Sign in
Active, not recruitingPhase 2

Assessing a Clinically-meaningful Opioid Withdrawal Phenotype

Key facts

Who runs it
University of Maryland, Baltimore
Where
Baltimore, United StatesSee the site
Trial code
Status
Active, not recruiting
Phase
Phase 2
People taking part
60 people, planned
Started
1 Dec 2021
Expected to end
28 Feb 2027
Type of study
Interventional
Treatments tested
  • Hydromorphone
  • Naloxone + lofexidine pretreatment
  • Naloxone + placebo pretreatment
  • Lofexidine
Record updated
12 November 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • 18 years - 65 year old
  • Opioid-positive urine sample
  • Current opioid use disorder with evidence of physical dependence
  • Interest in undergoing opioid taper

Who cannot take part

  • History of myocardial infarction
  • Subjects who are positive for hepatitis B surface antigen and/or hepatitis C antibody with liver function tests outside the normal range (persons with a positive hepatitis C antibody and normal liver functions tests are NOT excluded from the study)
  • Significant mental health or physical disorder, or life circumstances, that is expected to interfere with study participation
  • Evidence of physical dependence on alcohol or benzodiazepines that requires medical intervention
  • Being pregnant or breastfeeding
  • Enrolled in methadone or buprenorphine maintenance treatment
  • Clinically significant hypotension (<90/60mmHg) or bradycardia (<45bpm)

Where in United States

  • University of MarylandBaltimore, United States

About the trial

What the trial wants to find out

Evaluate individual differences in the expression of opioid withdrawal symptoms in persons with opioid use disorder (OUD) while completing a clinically-indicated medication taper.

The group in the trial

  • Within-subject designOther group

    All participants will undergo the same study design, which includes hydromorphone stabilization (days 1-5), two naloxone challenges (scheduled during morphine stabilization), lofexidine-assisted taper (days 6-10), and transition to aftercare (day 11).

    Treatment: Hydromorphone, Naloxone + lofexidine pretreatment, Naloxone + placebo pretreatment, and Lofexidine

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
12 November 2026